epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-405, Phase III. Recruiting

A rare inherited neuromuscular disorder (genetically confirmed)

TSR-405 against placebo in an inherited neuromuscular disorder. Sponsor: Tailspin Rare Diseases (fictional), Rare disease.

When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.

Study and plan

Tailspin Rare Diseases (fictional), Phase III, Rare disease. Month 0 is September 2024.
Randomise 64 (drop-out 15%) and screen about 146 (screen failure 56%)
Mar 2027
Confidence wanted
Sites per country
Edit the site counts in the table below
How much sites differ
Spread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
  • Central finish (P50)Aug 2030month 71.4
  • Fast case (P10)Jan 2029month 52.5
  • Slow case (P90)Not reachedwithin eight years
  • Chance of meeting the deadline0%wanted 85%
  • Sites1819% likely to recruit nobody
  • Patients to screen146to randomise 64

Likely to finish in August 2030, 41 months after the deadline

EPI-405, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast; the line marked Actual is recruitment so far

Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
MonthFast caseCentralSlow caseActual
Sep 20240000
Mar 20250000
Sep 20254201
Mar 202612734
Sep 2026211377
Mar 2027302012–
Sep 2027392616–
Mar 2028483220–
Sep 2028573924–
Mar 2029644528–
Sep 2029645133–
Mar 2030645837–
Sep 2030646441–
Mar 2031646445–
Sep 2031646449–
Mar 2032646454–
Sep 2032646458–

Source: epiClinical Poisson-gamma simulation; actual recruitment to September 30th 2026. All data synthetic.

How likely is it to finish by a given month?

Almost no chance of finishing by March 2027

Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 0 of 100 dots finish in time

Drag the handle or
In time: 0%Median Aug 2030 · 15 dots not complete by Sep 2032Late: 100%

Source: epiClinical Poisson-gamma simulation

Show data
Chance that recruitment is complete by the end of each month
MonthChance complete by then
Sep 20240%
Mar 20250%
Sep 20250%
Mar 20260%
Sep 20260%
Mar 20270%
Sep 20270%
Mar 20282%
Sep 20285%
Mar 202913%
Sep 202924%
Mar 203038%
Sep 203051%
Mar 203163%
Sep 203172%
Mar 203279%
Sep 203285%

Countries

UseCountryPatients per site per monthSites open betweenCapSitesPatients by finish
United States
0.048
  • Therapeutic area: 0.100 Rare disease baseline
  • Country: ×0.75 United States
  • Site type: ×0.991 Usual mix in United States, leaning to academic sites
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×1 Standard ×1
  • Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
  • Competing trials: ×1.1 None ×1.1
month 6.0 to 12.1 10017
United Kingdom
0.054
  • Therapeutic area: 0.100 Rare disease baseline
  • Country: ×0.85 United Kingdom
  • Site type: ×0.985 Usual mix in United Kingdom, leaning to academic sites
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×1 Standard ×1
  • Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
  • Competing trials: ×1.1 None ×1.1
month 5.9 to 11.9 4413
Spain
0.064
  • Therapeutic area: 0.100 Rare disease baseline
  • Country: ×1 Spain
  • Site type: ×0.987 Usual mix in Spain, leaning to academic sites
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×1 Standard ×1
  • Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
  • Competing trials: ×1.1 None ×1.1
month 9.5 to 15.5 7111
Poland
0.092
  • Therapeutic area: 0.100 Rare disease baseline
  • Country: ×1.4 Poland
  • Site type: ×1.02 Usual mix in Poland, leaning to academic sites
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×1 Standard ×1
  • Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
  • Competing trials: ×1.1 None ×1.1
month 13.0 to 19.0 4110
Turkey
0.063
  • Therapeutic area: 0.100 Rare disease baseline
  • Country: ×1 Turkey
  • Site type: ×0.981 Usual mix in Turkey, leaning to academic sites
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×1 Standard ×1
  • Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
  • Competing trials: ×1.1 None ×1.1
month 7.9 to 13.9 184
India
0.069
  • Therapeutic area: 0.100 Rare disease baseline
  • Country: ×1.1 India
  • Site type: ×0.967 Usual mix in India, leaning to academic sites
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×1 Standard ×1
  • Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
  • Competing trials: ×1.1 None ×1.1
month 7.9 to 13.9 158

Country risks to weigh when choosing sites

United States

Two sourced risks

  • All sites

    The first US site opens quickly, but the rest of the US sites open slowly.

    The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B

    Tightens: site activation overdue

  • All sites

    Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.

    Racial and ethnic under-representation · PB-12 · grade A

United Kingdom

Two sourced risks

  • Some sites

    Costing and contracting were the longest start-up step; the national contract has shortened it.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • If it recurs

    The regulator's backlog of 2023 was cleared, but could recur.

    Regulator assessment backlog · POL-02 · grade A

Spain

Two sourced risks

  • All sites

    Site contracts took 117 days in 2016 and about 90 after national templates.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

Poland

Two sourced risks

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

  • All sites

    A central ethics committee reviews every study; its effect on timelines is not measured.

    Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B

Turkey

Four sourced risks

  • All sites

    Ethics committees fell from 145 to 49 in 2024, cutting review capacity.

    Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024) · RW-05 · grade B

    Tightens: site activation overdue

  • All sites

    A fixed pharmaceutical exchange rate has caused repeated medicine shortages.

    Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026) · RW-07 · grade D

    Tightens: study drug at the site

  • All sites

    Start-up time has not been measured since CRO data from 2014 and 2015.

    Start-up time for India and Turkey is unmeasured · PM-04 · grade C

  • If it recurs

    Sites in the south-east lie in the 2023 earthquake zone.

    Major earthquake in a site region · SH-11 · grade C

India

Two sourced risks

  • All sites

    Vulnerable participants in trials of new drugs need an audio-visual record of their consent.

    Mandatory audio-visual consent for all participants · RW-03 · grade C

    Tightens: consent findings

  • All sites

    Start-up time is unmeasured beyond the statutory 90 working days.

    Start-up time for India and Turkey is unmeasured · PM-04 · grade C

    Tightens: site activation overdue

Risk-register entries; the choice of entries per country is epiClinical's.